Solid IO Launches on World Cancer Day: A New Era in Precision Oncology

On World Cancer Day, a day dedicated to raising awareness and driving action toward better outcomes for those affected by cancer, Solid IO officially launches its new website—marking the beginning of a mission to bring precision, clarity, and innovation to cancer treatment.

At Solid IO, we believe that cancer care should be as precise and personal as the individuals it serves. Our organ-on-chip technology is redefining how therapies are selected, ensuring that each patient’s unique tumor environment is considered when making treatment decisions. With real-time, patient-specific insights, our platform is designed to eliminate uncertainty, optimize clinical trials, and accelerate the development of next-generation immunotherapies.

"World Cancer Day is about action. At Solid IO, our action is to end the guesswork in cancer care by delivering technology that makes precision oncology a reality," says Noora Hujala, CEO and co-founder of Solid IO.

‍

A mission to transform cancer care

The challenge in oncology today is that many treatments still rely on trial-and-error approaches. Solid IO is changing that by replicating a patient’s tumor microenvironment in a lab setting, allowing researchers and clinicians to see—before treatment begins—how an individual’s cancer and immune system will respond. This innovation is set to impact cancer drug development, patient stratification for clinical trials, and the future of immunotherapy.

“Technology evolves, medicine advances—but at the core of it all is the patient, waiting for the right treatment,” adds Hujala. “Our mission is to give clinicians the insights they need to select the most effective therapy from day one.”

‍

Driving change through collaboration

Solid IO is built on a foundation of scientific excellence and collaboration. By working with pharmaceutical innovators, biotech firms, and leading cancer research centers, we are ensuring that groundbreaking discoveries translate into real-world patient impact.

As we launch on World Cancer Day, we invite partners, researchers, and investors to join us in accelerating the next era of precision medicine and immunotherapy.

‍

Together, we can make personalized treatment accessible, effective, and truly life-changing.

‍

Further Information

CEO Noora Hujala – noora.hujala@solid-io.com, +358 50 341 4801

CSO Dr. Heidi Haikala – heidi.haikala@solid-io.com

‍